Eli Lilly's oral weight-loss drug Foundayo reduced breathing interruptions by up to 44% among obese adults with moderate-to-severe sleep apnea in a late-stage clinical trial.

Eli Lilly’s Foundayo Cuts Sleep Apnea Symptoms by 44%

Foundayo Reduces Night-Time Breathing Interruptions in Obese Adults, Study Finds

By News Desk On Nov 10, 2026

WASHINGTON: (News Desk) – US pharmaceutical company Eli Lilly announced on Monday that its oral weight-loss medication, Foundayo, significantly reduced breathing interruptions during sleep among adults with obesity suffering from moderate-to-severe obstructive sleep apnea.

The drug achieved the primary objective of a late-stage clinical trial, demonstrating an average reduction of up to 44% in breathing interruptions after 52 weeks of treatment, according to the company.

The results were measured using a diagnostic scale commonly employed to assess the severity of sleep apnea.

Obstructive sleep apnea is a sleep disorder in which the upper airway repeatedly collapses during sleep, causing breathing interruptions, reducing oxygen levels in the blood and disrupting normal sleep patterns.

The findings highlight the potential of Foundayo as a treatment option for people living with obesity and moderate-to-severe sleep apnea.